Treatment Strategies for Myocardial Recovery in Heart Failure Andrew J. Lenneman, MD * Emma J. Birks, MD, PhD, FRCP
|
|
- June Baker
- 6 years ago
- Views:
Transcription
1 Curr Treat Options Cardio Med (2014) 16:287 DOI /s Heart Failure (W Tang, Section Editor) Treatment Strategies for Myocardial Recovery in Heart Failure Andrew J. Lenneman, MD * Emma J. Birks, MD, PhD, FRCP Address *Division of Cardiovascular Medicine, University of Louisville, Rudd Heart and Lung Center, 201 Abraham Flexner Way, Suite 1001, Louisville, KY 40202, USA andrew.lenneman@louisville.edu emma.birks@louisville.edu Published online: 4 February 2014 * Springer Science+Business Media New York 2014 This article is part of the Topical Collection on Heart Failure Keywords Heart failure I Treatment I Ventricular assist device I Recovery I LVAD Opinion statement Heart failure is a progressive disorder characterized by adverse left ventricular remodeling. Until recently, this has been thought to be an irreversible process. Mechanical unloading with a left ventricular assist device (LVAD), particularly if combined with neurohormonal blockade with heart failure medications, can lead to a reversal of the heart failure phenotype, a process called reverse remodeling. Reverse remodeling refers to the regression of pathologic myocardial hypertrophy and improvement in LV chamber size that can occur in response to treatment. Myocardial recovery is the sustained normalization of structural, molecular, and hemodynamic changes sufficient to allow explant of the LVAD. Despite the fact that reverse remodeling is commonly seen in LVAD patients in clinical practice, myocardial recovery sufficient to allow device explantation is still rare. Previous experience suggests that young patients with short duration of heart failure and less myocardial fibrosis may be more likely to recover. Alternatively, it may just be that clinicians make a greater effort to recover these subgroups. A combined approach of mechanical unloading with LVADs and pharmacological management, together with regular testing of underlying myocardial function with the pump reduced to a speed at which it is not contributing, can increase the frequency of sustained recovery from heart failure. The goal is to achieve optimal unloading of the myocardium, combined with pharmacologic therapy aimed at promoting reverse remodeling. Myocardial recovery must be considered as a therapeutic target. Clinical variables such as pump speed and blood pressure must be optimized to promote maximal unloading, leading to reverse remodeling and myocardial recovery. Frequent echocardiographic and hemodynamic evaluation of underlying myocardial function must be performed. The combination of LVAD therapy with optimal neurohormonal blockade appears promising as an approach to myocardial recovery. In addition,
2 287, Page 2 of 9 Curr Treat Options Cardio Med (2014) 16:287 there is a growing body of translational research which, when combined with LVADs, may further promote more durable recovery. Strategies to thicken the myocardium to enhance the durability of recovery prior to explantation, such as clenbuterol (which induces physiological hypertrophy ), or intermittently reducing the pump speed to increase myocardial load may be beneficial. Emergence of cardiac stem cells and alternative biologic agents, when added to current therapies, may have a complementary role in promoting and maintaining myocardial recovery. This review will summarize both current strategies and emerging therapies. Introduction Heart failure (HF) is a major cause of morbidity and mortality worldwide. The central feature in the pathologic progression of heart failure is left ventricular remodeling [1], which refers to the adverse structural, molecular, and cellular changes that occur. These changes are expressed clinically as increases in end-diastolic and end-systolic volumes, myocyte hypertrophy, interstitial fibrosis, and changes in LV chamber geometry to a more spherical shape, usually leading to a decline in ejection fraction [2, 3]. Heart failure treatments are aimed at stopping the progression and reversing the maladaptive remodeling process. Neurohormonal modulation has been the foundation of heart failure treatment for the past two decades. In clinical practice, medical treatment alone has frequently been shown to promote reverse remodeling, leading to myocardial recovery. Spontaneous myocardial recovery is seen in some clinical settings, such as acute myocarditis, peripartum cardiomyopathy, and tachycardia-induced cardiomyopathy, among others. Myocardial recovery is thought to be more common under the above-mentioned clinical conditions partly as a result of lower burden of myocardial fibrosis, and thus many of the pharmacologic, mechanical, and biologic heart failure therapies are aimed at altering the degree of myocardial fibrosis. Excessive scarring and fibrosis may limit the capacity for myocardial recovery [4]. An increasing body of evidence suggests that LVAD unloading can reverse the pathologic molecular, cellular, and structural changes associated with chronic heart failure [5]. This process of reverse remodeling can lead to myocardial recovery, i.e., the sustained normalization of myocardial structure and function following the removal of mechanical support. While reverse remodeling can occur in response to pharmacologic therapy alone, it is often a marked response to LVAD mechanical unloading, and combining the two is likely to lead to increased incidence of recovery. Despite these favorable molecular changes, myocardial recovery sufficient to allow device explant varies widely in clinical practice (Table 1). The myocardial changes seen in response to LVAD unloading in patients with chronic HF demonstrate the plasticity of the molecular structure and function in cardiomyopathies. LVADs provide a unique opportunity to study the process of reverse remodeling and how it relates to myocardial recovery. LVAD support allows administration of HF therapies at high doses that are often not tolerated prior to pump implant due to hypotension and renal dysfunction. Once good flow is restored using the VAD, these advanced heart failure patients are able to tolerate these medications at much higher doses. LVADs also provide a relatively safe platform for the delivery of promising novel biologic and cell-based therapies. Treatment Diet and lifestyle Exercise training has been shown to improve quality of life in patients with heart failure [6, 7]. The role of exercise training in myocardial recovery, however, is less well defined. Exercise training has been shown to be safe in
3 Curr Treat Options Cardio Med (2014) 16:287 Page 3 of 9, 287 Table 1. Summary of myocardial recovery trial results Study Year Number Recovery overall, N (%) Recovery nonischemic, N (%) Mancini et al. [36] (4.5) 4 (8) Farrar et al. [37] (8.1) 22 (8.1) Birks et al. [23] (73.3) 11 (73) Dandel et al. [38] (18.5) 35 (18.5) Birks et al. [24 ] (63.2) 12 (63.2) Patel et al. [39] (14.3) 3 (23.1) LVAD patients, and a recent study demonstrated that exercise training showed a trend toward greater improvement in exercise capacity and quality of life when compared to a control group [8]. Pharmacologic treatment Neurohormonal blocking medications are used in high doses to promote reverse remodeling. HF medications have been shown to reverse pathologic hypertrophy and normalize cellular metabolic functions, as well as to improve mortality and functional status. Many advanced heart failure patients are unable to tolerate high doses of HF medications due to hypotension and renal failure. Following LVAD implant, patients are better able to tolerate high doses of these medications. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce the rate of adverse LV remodeling and slow or prevent progressive LV dilation, both following acute myocardial infarction (MI) [9] and in nonischemic cardiomyopathies [10, 11]. Similar findings have been demonstrated upon administration of angiotensin receptor blockers (ARBs) [12]. ACE inhibitors (ACEi) and ARBs are used in combination to promote reverse remodeling and myocardial recovery in patients supported with an LVAD [11]. ACE inhibition has been associated with decreased myocardial collagen content decreased LV mass, and reduced myocardial stiffness [11, 13] in LVAD patients. Combining ACEi and ARBs leads to full blockade of the receptors and enhanced endothelial function due to increased concentrations of bradykinin. However, clinical trials of dual renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients have reported mixed results. Notably, in all of the ARB add-on trials, addition of an ARB to an ACE inhibitor led to increased rates of hypotension, renal dysfunction, and hyperkalemia [14, 15]. In LVAD patients, however, both renal function and blood pressure are supported by the VAD, so this is an ideal population to tolerate both ACEi and ARBs, particularly as maximal doses of both are administered [16]. In patients where myocardial recovery is the treatment goal, ARBs are added to ACEi to achieve maximum receptor blockade to promote reverse remodeling [16]. Goal dosage lisinopril, 40 mg daily losartan, 150 mg daily
4 287, Page 4 of 9 Curr Treat Options Cardio Med (2014) 16:287 Contraindications Main drug interactions Main side effects Cost/cost effectiveness hyperkalemia, renal failure, angioedema, previous reactions antihypertensive actions potentiated by volume depletion; use with caution in hyperkalemia cough (ACEi), renal insufficiency inexpensive Beta-adrenergic receptor (β-ar) blockers Several large randomized trials have demonstrated a survival benefit with beta-blocker therapy in symptomatic heart failure [17], which is when heart failure results in activation of the sympathetic nervous system. High catecholamine levels are not only a marker of disease, but are a direct contributor to heart failure progression. Beta-blockers can induce reverse remodeling in heart failure by improving myocyte contractility, contractile reserve, and calcium handling. Beta-blockers improve LV systolic function and reduce LV dimensions. Goal dosage Contraindications Main drug interactions Main side effects Cost/cost effectiveness carvedilol, mg three times daily metoprolol succinate, 200 mg daily bisoprolol, 10 mg daily symptomatic bradycardia antiarrhythmic drugs, calcium channel blockers bradycardia, increased airway resistance, hypoglycemia, fatigue, depression inexpensive Aldosterone antagonists Aldosterone receptors are upregulated in heart failure and may contribute to adverse myocyte hypertrophy and fibrosis. Multiple randomized trials have demonstrated a mortality benefit in heart failure patients treated with spironolactone [18]. Treatment with aldosterone antagonists also reduces fibrosis and improves cardiac function in patients with nonischemic cardiomyopathy and following acute myocardial infarction. Standard dosage spironolactone, 25 mg daily Contraindications hyperkalemia, renal failure Main drug interactions: Main side effects hyperkalemia, renal failure Cost/cost effectiveness inexpensive Assistive devices Left ventricular assist devices Myocardial changes associated with mechanical unloading with LVADs Mechanical unloading with an LVAD promotes reverse remodeling. The marked unloading of the ventricle with an LVAD leads to regression of cellular hypertrophy, improved calcium handling, improved beta-receptor
5 Curr Treat Options Cardio Med (2014) 16:287 Page 5 of 9, 287 Table 2. Clinical therapies that reverse LV remodeling Beta-adrenergic-receptor blockers ACE inhibitors and angiotensin-receptor blockers Aldosterone antagonists Biventricular pacing LV assist devices density, and improved collagen handling [1, 19, 20 ]. Clinically, LVAD unloading can lead to reduced LV dimensions and LV end-diastolic pressure (LVEDP) as well as improvement in LV ejection fraction (LVEF) [21]. In published studies, a strategy combining LVAD mechanical unloading with specific pharmacologic interventions has been shown to maximize the incidence and promote the durability of myocardial recovery [21, 22, 23, 24 ]. We designed a strategy in which pharmacologic medications known to promote reverse remodeling are started early after LVAD implant and uptitrated to maximum target doses (see Table 2). Additionally, LVAD mechanical pump speed is optimized to promote maximal mechanical unloading of the LV; using echocardiographic guidance, pump speed is adjusted, with the goal of decreasing LV chamber dimensions while maintaining the LV septum in the midline with closure of the aortic valve and minimizing mitral regurgitation. Optimal blood pressure control must be achieved in parallel with increasing pump speed. Continuous-flow LVADs are afterload-dependent, and hence increased afterload will decrease pump flow and reduce LV unloading. Therefore, the afterload reduction provided by the above-described medications will also increase pump flow and further unload the heart. In order to truly assess the underlying myocardial function, evaluations must then be conducted at regular intervals with the pump speed reduced to a level at which no net forward or reverse flow is provided [22 ]. LV function is assessed by echocardiography and exercise and hemodynamic studies, all performed at no net forward or reverse flow. Table 4 summarizes our algorithm for the clinical evaluation of myocardial recovery. Clenbuterol as adjuvant therapy At Harefield hospital near London, researchers developed a strategy of LVAD unloading with specific pharmacological interventions. The strategy was di- Table 3. Target doses of heart failure medications used in combination with LVAD unloading Lisinopril 40 mg daily Carvedilol 25 mg tid or 50 mg bid Spironolactone 25 mg daily Digoxin mg daily Losartan 150 mg daily
6 287, Page 6 of 9 Curr Treat Options Cardio Med (2014) 16:287 Table 4. Algorithm for promoting and testing for myocardial recovery following LVAD implantation Immediately post-op, following LVAD Early addition of HF medications (as soon as inotropes are weaned) to induce implant "reverse remodeling" with rapid uptitration of HF meds to high target doses Before discharge or first clinic visit post 2D Echo with LVAD at full support to maximize pump speed for unloading implant Starting at 6 weeks after implantation "Low-speed" Echo is performed, goal EF 945 % with pump down and regularly repeated 6-minute walk With LVAD at "low speed"(as part of the echo test) Goal: distanced walked is greater than 450 m and LVEF 945 % at low speed Cardiopulmonary exercise testing LVAD at full support LVAD at "low speed" Goal: peak VO2 916 ml/kg/min Right heart catheterization LVAD at full support LVAD at "low speed for 15 min Goal: PCWP G15, Cardiac Index92.5 L/min/m 2 Low speed is the pump speed at which there is no forward or reverse flow 22 vided into two phases. The first phase consisted of maximal unloading of the myocardium using LVADs combined with high-dose reverse-remodeling HF medications. Once maximal reverse remodeling was achieved, patients were switched to β1-selective beta-blockers, with the addition of clenbuterol to promote physiologic hypertrophy [23, 24, 25] (Tables 3 and 4). Clenbuterol is a selective β-2 adrenergic receptor agonist and a potent synthetic analog to epinephrine. It has been shown to induce a physiologic myocyte hypertrophy in rat models [26, 27]. The goal here is to induce physiologic hypertrophy after reverse remodeling has occurred to enhance the durability of myocardial recovery. Explantation Another important aspect of the myocardial recovery strategy is to use a careful explant technique aimed at minimizing any trauma to the explanted heart while it is fragile (i.e., while it is being loaded again after a long period of unloading). This can be achieved in one of two ways. The first is an explant technique that uses a short period of femoral cardiopulmonary bypass with minimal mobilization, i.e., as minimally invasive a technique as possible [28, 29]. The second method uses a felt plug rapidly inserted into the hole when the inlet cannula is removed, which avoids cardiopulmonary bypass altogether [30]. Heart failure medications are restarted following explantation and again uptitrated to maximal doses [23, 24 ]. Cardiac resynchronization therapy (CRT) Many patients with HF also have electric conduction abnormalities leading to ventricular dyssynchrony. Cardiac resynchronization therapy (CRT) involves biventricular pacing to reduce dyssynchrony and improve ventricular function, leading to reduction of LV dilation and hypertrophy [31, 32].
7 Curr Treat Options Cardio Med (2014) 16:287 Page 7 of 9, 287 Global cardiac function improvement and the reverse remodeling effects of CRT are greater in patients with nonischemic cardiomyopathy. There is a small group of patients, called super responders, whose LV function improves to normal or near-normal values [33]. Those with QRS duration greater than 150 ms with left bundle branch block (LBBB) morphology are most likely to benefit from CRT. The precise role of CRT in promoting myocardial recovery in patients supported with an LVAD is not well-defined, and this is an area in need of further investigation. Emerging therapies Phosphodiesterase type 5 (PDE5) inhibitors PDE5 inhibitors are widely used as an adjunctive therapy in heart failure patients with pulmonary hypertension. PDE5 inhibition enhances NO signaling by increasing the cyclic guanosine monophosphate (cgmp) availability, and has been shown to improve diastolic function in patients with heart failure [34]. Further study is needed to define its role, if any, in myocardial recovery. Stem cells Novel biologic agents Recent studies of stem cell-based therapies for heart failure indicate that current techniques have the potential to improve LV function. Stem cells offer the possibility of cardiac tissue regeneration through repair or replacement of damaged or lost myocytes. Clinical trial results have been encouraging, but further study is needed to determine optimal cell types and delivery methods to maximize results. Combining LVAD mechanical unloading with stem cell regeneration could lead to more durable myocardial recovery from HF. Other novel biological agents may have a future role in myocardial recovery. MicroRNAs, for example, have been proven to be powerful modifiers in many cardiovascular disease states, including heart failure. They have been shown to play an important role in cardiac development and myocyte proliferation, and likely play an important role in the remodeling process [35]. The growth factor neuregulin (NRG) has been shown to play a role in cardiac remodeling, and evidence from early clinical trials indicates that treatment with recombinant NRG improves LV systolic functions. These promising discoveries represent important potential therapeutic targets which, when combined with mechanical unloading with an LVAD, may increase the incidence and durability of myocardial recovery. Compliance with Ethics Guidelines Conflict of Interest Dr. Andrew J. Lenneman declares no potential conflicts of interest relevant to this article. Dr. Emma J. Birks has received grants.
8 287, Page 8 of 9 Curr Treat Options Cardio Med (2014) 16:287 Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors. References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: Of importance Of major importance 1. Birks EJ, George RS. Molecular changes occurring during reverse remodelling following left ventricular assist device support. J Cardiovasc Transl Res. 2010;3: Mann DL, Burkhoff D. Is myocardial recovery possible and how do you measure it? Curr Cardiol Rep. 2012;14: This is a good discussion of myocardial recovery in heart failure and how reverse remodeling relates to myocardial recovery. 3. Frazier OH, Myers TJ. Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg. 1999;68: Segura AM, Frazier OH, Demirozu Z, Buja LM. Histopathologic correlates of myocardial improvement in patients supported by a left ventricular assist device. Cardiovasc Pathol. 2011;20: Mann DL, Burkhoff D. Myocardial expression levels of micro-ribonucleic acids in patients with left ventricular assist devices signature of myocardial recovery, signature of reverse remodeling, or signature with no name? J Am Coll Cardiol. 2011;58: Belardinelli R, Georgiou D, Cianci G, Purcaro A. 10- year exercise training in chronic heart failure: a randomized controlled trial. J Am Coll Cardiol. 2012;60: O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. Jama. 2009;301: Hayes K, Leet AS, Bradley SJ, Holland AE. Effects of exercise training on exercise capacity and quality of life in patients with a left ventricular assist device: a preliminary randomized controlled trial. J Heart Lung Transplant. 2012;31: St John Sutton M, Lee D, Rouleau JL, et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107: Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91: Klotz S, Danser AH, Foronjy RF, et al. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol. 2007;49: Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362: Milting H, Kassner A, Arusoglu L, et al. Influence of ACE-inhibition and mechanical unloading on the regulation of extracellular matrix proteins in the myocardium of heart transplantation candidates bridged by ventricular assist devices. Eur J Heart Fail. 2006;8: Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensinconverting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14: Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol. 2013;10: Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374: Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9: Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341: Hall JL, Fermin DR, Birks EJ, et al. Clinical, molecular, and genomic changes in response to a left ven-
9 Curr Treat Options Cardio Med (2014) 16:287 Page 9 of 9, 287 tricular assist device. J Am Coll Cardiol. 2011;57: Birks EJ. Molecular changes after left ventricular assist device support for heart failure. Circ Res. 2013;113: This comprehensive review describes the molecular and structural myocardial changes that occur in response to LVAD unloading. 21. George RS, Yacoub MH, Tasca G, et al. Hemodynamic and echocardiographic responses to acute interruption of left ventricular assist device support: relevance to assessment of myocardial recovery. J Heart Lung Transplant. 2007;26: George RS, Sabharwal NK, Webb C, et al. Echocardiographic assessment of flow across continuousflow ventricular assist devices at low speeds. J Heart Lung Transplant. 2010;29: This study describes the optimal LVAD speed at which to assess the native LV function and the physiologic response to speed reduction. 23. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355: Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123: This study reports the clinical results of pharmacologic and mechanical unloading with continuous-flow LVAD to promote myocardial recovery, and reports clinical outcomes following device explant. 25. Yacoub MH. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J. 2001;22: Wong K, Boheler KR, Bishop J, Petrou M, Yacoub MH. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res. 1998;37: Soppa GK, Smolenski RT, Latif N, et al. Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am J Physiol Heart Circ Physiol. 2005;288:H Tansley P, Yacoub M. Minimally invasive explantation of implantable left ventricular assist devices. J Thorac Cardiovasc Surg. 2002;124: Haj-Yahia S, Birks EJ, Dreyfus G, Khaghani A. Limited surgical approach for explanting the HeartMate II left ventricular assist device after myocardial recovery. J Thorac Cardiovasc Surg. 2008;135: Cohn WE, Gregoric ID, Radovancevic B, Frazier OH. A felt plug simplifies left ventricular assist device removal after successful bridge to recovery. J Heart Lung Transplant. 2007;26: St John Sutton M, Ghio S, Plappert T, et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120: Moss AJ, Hall WJ, Cannom DS, et al. Cardiacresynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361: Reant P, Zaroui A, Donal E, et al. Identification and characterization of super-responders after cardiac resynchronization therapy. Am J Cardiol. 2010;105: Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4: Matkovich SJ, Van Booven DJ, Youker KA, et al. Reciprocal regulation of myocardial micrornas and messenger RNA in human cardiomyopathy and reversal of the microrna signature by biomechanical support. Circulation. 2009;119: Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation. 1998;98: Farrar DJ, Holman WR, McBride LR, et al. Long-term follow-up of Thoratec ventricular assist device bridgeto-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transplant. 2002;21: Dandel M, Weng Y, Siniawski H, et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation. 2008;118:S94 S Patel SR, Saeed O, Murthy S, et al. Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: a single-arm prospective study. J Heart Lung Transplant. 2013;32:
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationI have no disclosures. Disclosures
I have no disclosures Disclosures What is Heart Failure? Heart Failure (HF) A complex clinical syndrome where patients present with symptoms (i.e. dyspnea, fatigue, fluid retention) that result from any
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationVentricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationContemporary Advanced Heart Failure Therapy
Contemporary Advanced Heart Failure Therapy Andrew Boyle, MD Professor of Medicine Medical Director of Advanced Heart Failure Thomas Jefferson University Philadelphia, PA Audience Response Question 40
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationThe NEW Heart Failure Guidelines
The NEW Heart Failure Guidelines Daily Practice HF scenario of the Case Presentations HF as a complex and heterogeneous syndrome Several proposed pathophysiological mechanisms involving the heart and the
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationHeart Failure. Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy A Prospective Study
Heart Failure Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy A Prospective Study Emma J. Birks, FRCP, PhD; Robert S. George, BSc, BM,
More informationEvaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations
Review Evaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations Tohru Sakamoto, MD, PhD Left ventricular function on patients with
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationMedical Therapy after LVAD
Medical Therapy after LVAD Maria Frigerio 2nd Section of Cardiology, Heart Failure & Cardiac Transplant Unit DeGasperis CardioCenter, Niguarda Hospital, Milan, Italy Heart failure therapy in LVAD pts A
More informationSliwa et al. JACC 2004;44:
TREATMENT OF ADVANCED HEART FAILURE HEART DISEASE IN KENTUCKY Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac
More informationManagement of Heart Failure in Older Adults
Management of Heart Failure in Older Adults New Data, New Guidelines, New Challenges JOSE NATIVI, MD, MSCI Assistant Professor of Medicine Cardiovascular Director Amyloidosis Program DISCLOSURES - Advisory
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationHeart Transplantation is Dead
Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationDevice Therapy for Heart Failure
Device Therapy for Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics St Boniface General Hospital,
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationNew Strategies For Treating Patients With Chronic Heart Failure
New Strategies For Treating Patients With Chronic Heart Failure Barry Greenberg MD Professor of Medicine Director, Advanced Heart Failure Treatment Program University of California, San Diego Disclosures
More informationEffect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin
Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular
More informationThe role of angiotensin II receptor blockers in the management of heart failure
European Heart Journal Supplements (2005) 7 (Supplement J), J10 J14 doi:10.1093/eurheartj/sui057 The role of angiotensin II receptor blockers in the management of heart failure John J.V. McMurray* Department
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationHeart Failure. Jay Shavadia
Heart Failure Jay Shavadia Definition Clinical syndrome characterized by: Symptoms: breathlessness at rest or on exercise, fatigue, tiredness or ankle swelling AND Signs: tachycardia, tachypnea, pulmonary
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationDiastolic Heart Failure. Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012
Diastolic Heart Failure Edwin Tulloch-Reid MBBS FACC Consultant Cardiologist Heart Institute of the Caribbean December 2012 Disclosures Have spoken for Merck, Sharpe and Dohme Sat on a physician advisory
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationHeart Failure in 2012 with reference to NICE Guidance Dr Maurice Pye Consultant Cardiologist York District Hospital
Heart Failure in 2012 with reference to NICE Guidance 2010 Dr Maurice Pye Consultant Cardiologist York District Hospital A little over elaborate,do not include ECG or CXR If clinical suspicion is high
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationDiastolic Heart Failure
Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationIncidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction
Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness
More informationPathophysiology: Heart Failure. Objectives
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationTreatment of Heart Failure: Current Recommendation Waiz A
Treatment of Heart Failure: Current Recommendation Waiz A The impaired left ventricular emptying that characterizes heart failure may result from a variety of cardiac diseases, including myocardial ischaemia
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationValvular Guidelines: The Past, the Present, the Future
Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationUpdate on therapy for acute and chronic heart failure for family physicians Applying advances in outpatient management
Update on therapy for acute and chronic heart failure for family physicians Applying advances in outpatient management Authors: Abdullah Alsaeedi MD, FRCPC Division of internal Medicine Aljahra Hospital
More informationSara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012
Sara O. Weiss, MD Director, Heart Failure Services Virginia Mason Medical Center September 8, 2012 Disclosure: Dr. Weiss has no significant financial interest in any of the products or manufacturers mentioned.
More informationDiastolic Heart Failure Uri Elkayam, MD
Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationWomen s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women
Women s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women C. Noel Bairey Merz MD Medical Director and Barbra Streisand Women s Heart Center Preventive
More informationWHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES
WHEN TO REFER FOR ADVANCED HEART FAILURE THERAPIES Mrudula R Munagala, M.D., FACC CO- Director Heart Failure & Circulatory Support Program OklahomaHeart.com Heart Failure Prevalence Heart Failure affects
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationDrugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used in Heart Failure Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia Heart Failure Heart failure (HF), occurs when cardiac output is inadequate to
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationCardiopulmonary Support and Physiology. Prediction of cardiac function after weaning from ventricular assist devices
Liang et al Cardiopulmonary Support and Physiology Prediction of cardiac function after weaning from ventricular assist devices Hong Liang, MD, a Hansheng Lin, MD, b Yuguo Weng, MD, c Michael Dandel, MD,
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More information